The “Interval Walking in Colorectal Cancer” (I-WALK-CRC) study: Design, methods and recruitment results of a randomized controlled feasibility trial

Abstract Background Low physical activity level is associated with poor prognosis in patients with colorectal cancer (CRC). To increase physical activity, technology-based platforms are emerging and provide intriguing opportunities to prescribe and monitor active lifestyle interventions. The “Interv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contemporary clinical trials communications 2018-03, Vol.9 (C), p.143-150
Hauptverfasser: Banck-Petersen, Anna, Olsen, Cecilie K, Djurhuus, Sissal S, Herrstedt, Anita, Thorsen-Streit, Sarah, Ried-Larsen, Mathias, Østerlind, Kell, Osterkamp, Jens, Krarup, Peter-Martin, Vistisen, Kirsten, Mosgaard, Camilla S, Pedersen, Bente K, Højman, Pernille, Christensen, Jesper F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Low physical activity level is associated with poor prognosis in patients with colorectal cancer (CRC). To increase physical activity, technology-based platforms are emerging and provide intriguing opportunities to prescribe and monitor active lifestyle interventions. The “Interval Walking in Colorectal Cancer“(I-WALK-CRC) study explores the feasibility and efficacy a home-based interval-walking intervention delivered by a smart-phone application in order to improve cardio-metabolic health profile among CRC survivors. The aim of the present report is to describe the design, methods and recruitment results of the I-WALK-CRC study. Methods/Results: The I-WALK-CRC study is a randomized controlled trial designed to evaluate the feasibility and efficacy of a home-based interval walking intervention compared to a waiting-list control group for physiological and patient-reported outcomes. Patients who had completed surgery for local stage disease and patients who had completed surgery and any adjuvant chemotherapy for locally advanced stage disease were eligible for inclusion. Between October 1st, 2015, and February 1st, 2017, 136 inquiries were recorded; 83 patients were eligible for enrollment, and 42 patients accepted participation. Age and employment status were associated with participation, as participants were significantly younger (60.5 vs 70.8 years, P 
ISSN:2451-8654
2451-8654
DOI:10.1016/j.conctc.2018.01.008